Signaling Pathway
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody designed to selectively target the p19 subunit of interleukin-23 (IL-23). It exhibits a high binding affinity with a dissociation constant (K_D) of 0.138 nM for human IL-23. This specificity makes Brazikumab a valuable tool for the study of immune-mediated inflammatory disorders, particularly Crohn's disease.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Brazikumab (AMG 139) is a human IgG2 monoclonal antibody designed to selectively target the p19 subunit of interleukin-23 (IL-23). It exhibits a high binding affinity with a dissociation constant (K_D) of 0.138 nM for human IL-23. This specificity makes Brazikumab a valuable tool for the study of immune-mediated inflammatory disorders, particularly Crohn's disease. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
